崧盛股份(301002.SZ):擬與重慶精剛傳動針對“機器人諧波減速器及智能關節技術開發應用”進行技術開發合作
格隆匯6月23日丨崧盛股份(301002.SZ)公佈,公司與重慶精剛傳動科技有限公司(簡稱“重慶精剛傳動”)針對“機器人諧波減速器及智能關節技術開發應用”項目簽署《技術開發合同》,其中公司提供研發經費共計人民幣1,200萬元,重慶精剛傳動負責組建研發團隊及技術攻關。實現設計開發具備高精度、輕量化、智能化等高性能特性的諧波減速器、智能關節模組及關鍵零部件,並實現在機器人等工業領域的批量應用的開發目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.